BioCentury | Jan 19, 2018
Tools & Techniques

Synthetic expressions

...viral vectors, including retroviruses and AAVs 2016 Sartorius AG (Xetra:SRT) Evaluate and test synthetic promoters with Sartorius’...
BioCentury | May 11, 2015
Company News

Sartorius, Cell Therapy Catapult deal

...undisclosed grant from the U.K. government’s Innovate UK. The partners declined to provide further details. Sartorius AG...
BioCentury | Nov 3, 2014
Clinical News

Humira adalimumab: Phase III data

...Suppurativa Clinical Response (HiSCR) at week 12; change in hidradenitis suppurativa count, skin pain and Sartorius...
BioCentury | Sep 29, 2014
Clinical News

Humira adalimumab: Phase III data

...Suppurativa Clinical Response (HiSCR) at week 12; change in hidradenitis suppurativa count, skin pain and Sartorius...
BioCentury | Dec 9, 2013
Company News

Sartorius, TAP Biosystems Group deal

...approved Sartorius' offer to acquire TAP Biosystems for €33 million ($44.6 million ) in cash. Sartorius...
...phases of product and process development. The deal is expected to close by year end. Sartorius AG...
BioCentury | Mar 19, 2012
Clinical News

Humira adalimumab: Phase III started

...skin pain as measured by the patient's global assessment of skin pain and change in Sartorius...
BioCentury | Dec 19, 2011
Company News

Biohit, Sartorius AG deal

...Heinio, along with the employees and management team of the liquid handling business, transferred to Sartorius...
...succeeds Heinio as president and CEO (see BioCentury, Oct. 31). Biohit Oyj (HSE:BIOBV), Helsinki, Finland Sartorius AG...
BioCentury | Oct 31, 2011
Company News

Biohit, Sartorius AG deal

...and eight sales subsidiaries, is expected to close in December. Biohit Oyj (HSE:BIOBV), Helsinki, Finland Sartorius AG...
BioCentury | Aug 29, 2011
Financial News

Biohit completes private placement

...Raised: €2 million ($2.9 million) Shares: 677,966 Price: €2.95 Shares after offering: 13.6 million Investor: Sartorius...
BioCentury | Jun 11, 2007
Company News

Crucell, DSM Biologics N.V., Sartorius AG deal

...disclosed. Crucell N.V. (Euronext:CRXL; CRXL), Leiden, the Netherlands DSM Biologics N.V. , Heerlen, the Netherlands Sartorius AG...
Items per page:
1 - 10 of 13
BioCentury | Jan 19, 2018
Tools & Techniques

Synthetic expressions

...viral vectors, including retroviruses and AAVs 2016 Sartorius AG (Xetra:SRT) Evaluate and test synthetic promoters with Sartorius’...
BioCentury | May 11, 2015
Company News

Sartorius, Cell Therapy Catapult deal

...undisclosed grant from the U.K. government’s Innovate UK. The partners declined to provide further details. Sartorius AG...
BioCentury | Nov 3, 2014
Clinical News

Humira adalimumab: Phase III data

...Suppurativa Clinical Response (HiSCR) at week 12; change in hidradenitis suppurativa count, skin pain and Sartorius...
BioCentury | Sep 29, 2014
Clinical News

Humira adalimumab: Phase III data

...Suppurativa Clinical Response (HiSCR) at week 12; change in hidradenitis suppurativa count, skin pain and Sartorius...
BioCentury | Dec 9, 2013
Company News

Sartorius, TAP Biosystems Group deal

...approved Sartorius' offer to acquire TAP Biosystems for €33 million ($44.6 million ) in cash. Sartorius...
...phases of product and process development. The deal is expected to close by year end. Sartorius AG...
BioCentury | Mar 19, 2012
Clinical News

Humira adalimumab: Phase III started

...skin pain as measured by the patient's global assessment of skin pain and change in Sartorius...
BioCentury | Dec 19, 2011
Company News

Biohit, Sartorius AG deal

...Heinio, along with the employees and management team of the liquid handling business, transferred to Sartorius...
...succeeds Heinio as president and CEO (see BioCentury, Oct. 31). Biohit Oyj (HSE:BIOBV), Helsinki, Finland Sartorius AG...
BioCentury | Oct 31, 2011
Company News

Biohit, Sartorius AG deal

...and eight sales subsidiaries, is expected to close in December. Biohit Oyj (HSE:BIOBV), Helsinki, Finland Sartorius AG...
BioCentury | Aug 29, 2011
Financial News

Biohit completes private placement

...Raised: €2 million ($2.9 million) Shares: 677,966 Price: €2.95 Shares after offering: 13.6 million Investor: Sartorius...
BioCentury | Jun 11, 2007
Company News

Crucell, DSM Biologics N.V., Sartorius AG deal

...disclosed. Crucell N.V. (Euronext:CRXL; CRXL), Leiden, the Netherlands DSM Biologics N.V. , Heerlen, the Netherlands Sartorius AG...
Items per page:
1 - 10 of 13